[Calcium channel blockers increasing coronary blood flow via NO-dependent mechanism].
Asanuma
Hiroshi
H
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine.
Kitakaze
Masafumi
M
D000241:Adenosine / Q000502:physiology; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D001920:Bradykinin / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D003326:Coronary Circulation / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D007705:Kinins / Q000096:biosynthesis; D009569:Nitric Oxide / Q000096:biosynthesis / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000502:physiology; D052250:Nitric Oxide Synthase Type III; D018384:Oxidative Stress / Q000187:drug effects; D043782:Receptor, Bradykinin B2 / Q000502:physiology; D013268:Stimulation, Chemical
D002121:Calcium Channel Blockers; D007705:Kinins; D043782:Receptor, Bradykinin B2; D009569:Nitric Oxide; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D000241:Adenosine; D001920:Bradykinin